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Abstract
Background: Young women’s attendance at cervical screening in the UK is continuing 
to fall, and the incidence of invasive cervical cancer is rising.
Objectives: We assessed the preferences of non‐attending young women for alter‐
native ways of delivering cervical screening.
Design: Postal discrete choice experiment (DCE) conducted during the STRATEGIC 
study of interventions for increasing cervical screening uptake. Attributes included 
action required to arrange a test, location of the test, availability of a nurse navigator 
and cost to the National Health Service.
Setting and participants: Non‐attending young women in two UK regions.
Main outcome measures: Responses were analysed using a mixed multinomial logit 
model. A predictive analysis identified the most preferable strategy compared to cur‐
rent screening. Preferences from the DCE were compared with observed behaviours 
during the STRATEGIC trial.
Results: The DCE response rate was 5.5% (222/4000), and 94% of respondents 
agreed screening is important. Preference heterogeneity existed around attributes 
with strong evidence for test location. Relative to current screening, unsolicited self‐
sampling kits for home use appeared most preferable. The STRATEGIC trial showed 
this same intervention to be most effective although many women who received it 
and were screened, attended for conventional cytology instead.
Conclusions: The DCE and trial identified the unsolicited self‐sampling kit as the 
most preferred/effective intervention. The DCE suggested that the decision of some 
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1  | INTRODUC TION
For a growing proportion of young women, embarrassment, anxi‐
ety, fear and inconvenience around testing are barriers to cervical 
screening.1‐4 The reluctance of many to engage with the National 
Health Service (NHS) Cervical Screening Programme (CSP) is re‐
flected in national screening statistics. Five‐year screening coverage 
rates in England are lowest amongst 25‐ to 29‐year‐old women and 
are falling (72% in 2005 to 65% in 2017), whilst the incidence of in‐
vasive cervical cancer has begun to increase.5,6 Similarly in Scotland, 
non‐attendance is highest amongst young women, with a screen‐
ing uptake rate during 2017/2018 of just 62% in those aged 25 to 
29 years.7 Furthermore, screening uptake is known to be lower with 
increasing levels of deprivation, with uptake rates amongst young 
women shown to vary as much as 4% between highest and lowest 
deprivation categories.8,9 This is a concern and is driving research 
into tailored interventions aiming to address women’s barriers to 
screening and which could potentially be embedded within the ex‐
isting CSP to increase uptake.
The decision to invest in any such interventions should be in‐
formed by evidence on effectiveness and cost‐effectiveness. 
Complementary data on the acceptability of an intervention to 
women might also reassure policymakers that the intervention will 
work in routine practice. Discrete choice experiments (DCEs) offer 
a way of eliciting preferences for the characteristics or attributes 
of an intervention; they also provide information on the trade‐offs 
(the decision to sacrifice the benefits of one attribute in favour of 
another) that respondents are prepared to make between attributes. 
DCEs have been used in health‐care settings to improve the design 
and delivery of patient services.10‐12 Their use also extends to can‐
cer screening programmes; a systematic review identified 22 stated 
preference studies published between 1990 and 2013 addressing 
breast, cervical and colorectal cancer screening.13
The DCE reported in this paper was conducted as part of the 
STRATEGIC study (Strategies to Increase Cervical Screening Uptake 
at First Invitation) which evaluated novel interventions intended to 
make screening more acceptable to young women receiving their 
first invitation.14,15 Interventions were evaluated in a phased clus‐
ter randomized trial conducted in the Greater Manchester area of 
England and the Grampian area of Scotland. In phase 1, pre‐invita‐
tion information leaflets and Internet booking options were trialled 
to increase initial attendance. In phase 2, young women who had not 
attended within six months of an initial invitation were randomized to 
one of six alternatives: a human papillomavirus (HPV) self‐sampling 
kit (SSK) for home use which was trialled as an unsolicited (sent) and 
a solicited (offered) intervention, a pre‐specified timed appointment 
(PTA) for a routine screening test, access to a nurse navigator (NN) 
whom women could contact to discuss concerns about screening 
and for help in navigating the screening process, a choice between a 
PTA and the NN, or no further action. The feasibility of these inter‐
ventions was confirmed in a pilot study. The primary outcome mea‐
sure for phase 2 of the trial was uptake in screening at 12 months 
post‐initial invitation. Cost‐effectiveness was also assessed.15,16
The DCE was conducted simultaneously with the trial. Its ob‐
jectives were to determine young women’s preferences for the in‐
dividual characteristics of the phase 2 interventions and to predict 
which interventions were likely to be most preferable to women. 
The study design also afforded a unique opportunity to compare the 
effectiveness of the STRATEGIC interventions with their potential 
acceptability to women if implemented widely in the UK. Given the 
defining characteristics of the study cohort (a hard to reach, grow‐
ing group of young women about whom little is known regarding 
their preferences for screening interventions), this is a novel study 
which should be of interest to policymakers, clinicians, researchers 
and women themselves.
2  | METHODS
2.1 | Designing the discrete choice experiment
In a DCE, participants are presented with a number of questions, 
each asking them to make a choice between two or more alterna‐
tives (together referred to as a choice set). The alternatives within 
a choice set are described using a set of common attributes (eg in a 
study of follow‐up care, attributes might include frequency of fol‐
low‐up, clinical personnel seen and duration of appointment).10 Each 
attribute has values (levels), and the levels taken by at least one at‐
tribute are systematically varied between the alternatives (eg follow‐
up frequency might be annual in one alternative and 2 yearly in the 
other). Respondents then select their preferred alternative.17 Here, 
the alternatives considered were different means of delivering the 
CSP (see Table 1). The DCE was developed taking the following steps.
2.2 | Identifying attributes and levels
The published evidence around barriers to cervical screening helped 
develop a topic guide for planned qualitative interviews with 20‐30 
women.3,4 Interview invitations were sent to a sample of women 
women receiving the kit in the trial to attend for conventional cytology may be due to 
anxieties around home testing coupled with a knowledge that ignoring the kit could 
potentially have life‐changing consequences.
K E Y W O R D S
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invited to take part in phase 1 of STRATEGIC and to women in the 
phase 2 pilot study. It was the intention to use purposive sampling 
so as to conduct interviews in a mix of women offered the phase 2 
interventions (HPV SSK, PTA, NN), and furthermore in those who 
had accepted and declined the intervention. A first batch of 600 in‐
vitations yielded four respondents; a second batch of 500 yielded 
one additional respondent. These five women underwent semi‐
structured telephone interviews. All had been allocated the sent 
HPV SSK but prior to interview it was not known if they had used 
the kit. Interviews were digitally recorded, transcribed verbatim and 
analysed using deductive content analysis.18
For the women interviewed, four issues emerged as being im‐
portant. Flexibility, particularly around the booking process and 
attending for the screen (fitting this into busy daily life), was a key 
factor. Expertise was also important, with regard to self‐testing ver‐
sus testing by a health professional. The emotional impact of screen‐
ing was evident, centring upon the discomfort of testing (regardless 
of location), and the embarrassment of having a test administered 
by a health professional. Finally, women raised ideas around greater 
normalization of screening, including the provision of more informa‐
tion of the process, as well as increased use of reminders (delivered, 
eg by text message).
As only five women were interviewed, findings were reviewed 
against published evidence on the barriers to cervical screening 
and found to be broadly consistent. Together, STRATEGIC’s clini‐
cal, quantitative and qualitative teams ensured the finalized list of 
attributes captured aspects of screening that were important to 
women and also described features of the phase 2 interventions.
Table 1 shows these attributes, their levels, and how each relates 
to the interventions being studied. Inconvenience around the book‐
ing process was a concern, as was a dislike of the test per se, which 
potentially makes calling for an appointment difficult. As the phase 2 
interventions offered different approaches for arranging a screen (eg 
with a PTA the appointment is made for the woman), we included the 
attribute ‘Action required by you personally to arrange a test?’ with 
associated levels ‘Yes’ and ‘No’. The inconvenience of attending, cou‐
pled with the embarrassment of a gynaecological examination, could 
potentially be overcome by the use of a HPV SSK. Some women, 
however, have concerns around their competence to perform a 
home test.19 To account for these aspects, we included the attri‐
bute ‘Location of the test’ with levels ‘GP surgery/clinic’ and ‘Home’. 
Women’s perceived need for more information plus their fears 
around the examination could be allayed by a trained nurse prior to 
screening. As the NN could potentially be an adjunctive option with 
any of the interventions, it was included as an attribute in its own 
right. Finally, a cost attribute was included with four values reflecting 
the approximate costs to the NHS of each of the interventions.
2.3 | Experimental design
The attributes and levels in Table 1 combined to give 
2 × 2 × 2 × 4 = 32 possible profiles and 1024 (322) possible pairwise 
Attributes and levels
Interventions
PTA Sent HPV SSK Offered HPV SSK NN
Action required by you 
personally to arrange 
a test?
Yes ● ●
No ● ●
Location of the test
GP surgery/clinic ● ●a
Home ● ● ●b
Nurse available for 
discussion or help prior 
to appointment?
Yes ●
No ● ● ●
Cost of your test to the 
NHS
£8 ● ●
£20 ●b
£25 ●
£40 ●a
Abbreviations: HPV SSK, self‐sampling kit; NN, nurse navigator; PTA, pre‐specified timed 
appointment.
aNN plus clinic test. 
bNN plus HPV SSK. 
TA B L E  1   Characterization of phase 
2 STRATEGIC interventions through 
combinations of attributes (and levels) 
incorporating issues of known importance 
to non‐attending women
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choice tasks. To reduce the number of choice tasks, a D‐optimal 
design approach in Ngene 1.1.2 software was used.20,21 This 
method ensures that choice sets are chosen to provide a balance 
of attribute levels across the experiment (orthogonality), and that 
attributes within a choice set never take the same level value 
(thereby forcing respondents to trade on all attributes and elic‐
iting maximum information).22‐24 The design approach suggested 
little informational benefit would be gained by using more than 
16 choice sets, but given the challenges engaging these women 
with the qualitative interviews, we opted for 12 sets to reduce 
respondent burden (see Supplemental File 1).
2.4 | Piloting of the questionnaire
As well as the choice sets, women completing the questionnaire re‐
ported their general views on the current screening programme and 
provided demographic information. In addition to the paper‐based 
questionnaire, an online version was developed using LimeSurvey 
(www.limes urvey.org). The weblink was sent out with the paper‐
based questionnaire, thus providing women with a choice as to how 
to respond. To encourage participation, women were offered a £10 
high‐street voucher.
Piloting of the questionnaire took place between July and 
September 2014 in young women not responding to their initial 
screening invitation. The English and Scottish screening agen‐
cies identified eligible women and mailed out the questionnaires. 
One thousand questionnaires were sent to women in Greater 
Manchester (n = 650) and Grampian (n = 350), and 54 (5.4%) were 
returned (11/54 (20%) using the online version). Responding women 
appeared to complete the questionnaire without difficulty, and in 
response to a small number reporting, it was unclear when the NN 
would be available, the words ‘prior to the appointment’ (Table 1) 
were added. A graphic design team improved the look of the ques‐
tionnaire, the final version of which and the accompanying informa‐
tion leaflet are shown in the Supplemental File 1.
2.5 | Sample size
Sample size calculations for DCEs identify the minimum number 
of choice observations required to obtain reliable parameter es‐
timates from the statistical models used to analyse stated choice 
data. In this study, for example, one completed questionnaire pro‐
vided 12 choice observations. Applying the approach of Rose and 
Bliemer to response data from the pilot study showed that with 
sample sizes >150, it would be possible to estimate significant co‐
efficients for the action, nurse and cost attributes. The location 
attribute would require a sample size of 1151 (see Supplemental 
File 1).25
2.6 | Administering the final questionnaire
The main DCE data collection was carried out between mid‐July 
2015 and mid‐September 2015. Three thousand questionnaires 
were sent to women in Greater Manchester (n = 2000) and 
Grampian (n = 1000). Questionnaires were again mailed out by the 
English and Scottish screening agencies, who in conjunction with 
the STRATEGIC study research team, identified young women in 
the Greater Manchester and Grampian regions of Scotland who had 
been invited for but who had not yet attended for their first cervical 
cancer screen. Young women, for whom a screening result had been 
recorded, were not eligible.
2.7 | Statistical analysis
Descriptive statistics were used to summarize participant demo‐
graphics and women’s views of screening. For the 12 choice sets, we 
assumed each choice was made in accordance with random utility 
theory which states that when faced with two or more alternatives, 
each of which generate a level of utility (satisfaction), an individual 
will select the alternative maximizing their utility.17 As researchers 
cannot observe an individual’s utility, but do have information on the 
attributes of the alternatives being considered, and of the decision 
makers per se, regression‐based modelling can be used to explain 
the statistical relationship between observed factors and the deci‐
sion maker’s choices (more detail is provided in the Supplemental 
File 1). For this study, the explainable utility (V) of the nth individual 
for screening intervention ( i ) was estimated to be a linear and addi‐
tive function of each intervention’s attributes and levels as follows:
훼 is a constant term and if statistically significant suggests re‐
spondents have a general propensity to select alternative one over 
alternative two in choice sets, all else being equal. Its inclusion in the 
model allows this bias to be controlled for.17 As action, location and 
nurse are categorical variables, the sign of the estimated coefficients 
훽1, 훽2 and 훽3 denotes whether a move from the reference category 
for each variable (from no to yes for action, home to GP clinic for 
location and no to yes for nurse) results in an increase or decrease 
in overall utility. For cost, the directional change in utility resulting 
from an increase of £1 is given by 훽4.
Equation 1 assumes the incremental impact of an attribute on 
utility is the same for all women. In reality, different forms of hetero‐
geneity exist. It is possible to explain some of this heterogeneity by 
incorporating women’s characteristics in the explainable utility (V). 
However, a preferred alternative is to assume that there are differ‐
ent sources of heterogeneity that are not observable by the analyst 
and that are random. Accordingly, we estimated a random correlated 
parameter mixed logit model to account for this random heteroge‐
neity (see Supplemental File 1). During the estimation process, pa‐
rameter coefficients 훼, 훽1, 훽2 and 훽3 were assumed to follow a normal 
distribution and 훽4 (cost parameter) a lognormal distribution. Model 
results are presented as means and standard deviations for each 
parameter. Significant standard deviations indicate the presence of 
preference heterogeneity.
A predictive analysis was used to simulate hypothetical scenar‐
ios, each offering a dichotomous choice between the current CSP 
(1)Vni=훼+훽1Actionyes+훽2LocationGPsurg∕clinic+훽3Nurseyes+훽4Cost
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and a programme with attributes matching one of the STRATEGIC 
interventions. For each scenario, the probability that each alter‐
native was chosen as best was predicted by the model after set‐
ting each of the attributes to levels characterizing the alternative 
programmes. The current CSP was defined as follows: action re‐
quired to arrange a test? – ‘yes’, location of test? – ‘GP surgery/
clinic’, availability of a nurse? – ‘no’ and cost of test to the NHS 
– ‘£25’. When simulating results for the PTA for example, only 
the action attribute was switched from yes to no. Confidence in‐
tervals around the predicted probabilities were estimated using 
simulation, in which for each model coefficient, 1000 draws were 
generated from a multivariate normal distribution with means and 
covariance matrix from the original correlated mixed logit model. 
Predicted probabilities were computed for each sampled coeffi‐
cient and for each of the competing programmes, and then, 2.5th 
and 97.5th percentiles across 1000 predicted probabilities were 
identified.
Analyses were performed in Stata MP using the ‘mixlogit’ 
command.26,27
2.8 | The STRATEGIC trial results
In phase 2 of the STRATEGIC trial at 12 months post‐initial invita‐
tion, screening uptake in the no action (control) arm was 16.2%.14,15 
Only two of the interventions – the sent HPV SSK and the PTA – 
resulted in significantly higher 12‐month screening uptake rates of 
21.3% and 19.8%, respectively (associated odds ratios 1.51 [95% CI 
1.20‐1.91] and 1.41 [95% CI 1.14‐1.74]).14,15 The NN resulted in a sig‐
nificant reduction in screening uptake. Of the women who received 
a sent HPV SSK and were screened, more than two thirds underwent 
only a conventional cytology test.14,15
The accompanying cost‐effectiveness analysis concluded that 
the sent HPV SSK and PTAs were likely to be cost‐effective.16
3  | RESULTS
Of the 3000 questionnaires sent, 168 (5.6%) were completed (98 
[58%] from Greater Manchester, 68 [40%] from Grampian and 
with two women choosing not to say). One hundred and twenty‐
one (72%) postal questionnaires were returned and 47 (28%) 
women completed the survey online. The low response rate and 
implications of the sample size for the statistical modelling were 
discussed. As changes to the wording of the questionnaire be‐
tween the pilot and main surveys were minor and given the same 
experimental design was used, a pragmatic decision was made to 
combine the pilot and main surveys, giving a final sample of 222 
respondents and 2600 choice observations to estimate reliable 
parameter estimates for all four attributes. Figure 1 details the 
flow of participants.
3.1 | Descriptive data analysis
Table 2 shows respondents’ characteristics. Almost three fifths were 
from England and the overall mean age was 24.6 years. Women from 
Scotland were younger (reflecting the lower age threshold for com‐
mencement of screening in Scotland at the time). The majority of 
women were of White ethnicity and just under a half had been edu‐
cated to university level. Almost three fifths were in employment.
When presented with the statement ‘screening for cervical 
cancer is important’, almost two thirds of women (64%) indicated 
that they strongly agreed and a further 30% selected the ‘agree’ 
option.
3.2 | Discrete choice modelling analysis
Table 3 shows the mean coefficients for each attribute from the 
model. Each of the attributes had a significant impact upon women’s 
F I G U R E  1   Flow of women through the 
study
Questionnaires sent out in 
the pilot DCE (n = 1000)
Questionnaires 
not received 
(n = 946)
Questionnaires sent out in 
the main DCE (n = 3000)
Questionnaires 
received (n = 54)
Response rate = 5.4%
Full responses (n = 222)
Final response rate = 5.5%
Area
Greater Manchester (n = 29, 54%)
Grampian (n = 24, 44%)
Rather not say (n = 1, 2%)
Elicitation method
Postal (n = 43, 80%)
Internet (n = 11, 20%)
Questionnaires 
not received 
(n = 2832)
Questionnaires 
received (n = 168)
Response rate = 5.6%
Area
Greater Manchester (n = 98, 58%)
Grampian (n = 68, 40%) 
Rather not say (n = 2, 1%)
Elicitation method
Postal (n = 121, 72%)
Internet (n = 47, 28%)
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utility. The alternative specific constant was also significant (with a 
negative sign), suggesting that all else being equal, women selected 
the first of the two options presented. When considered in isola‐
tion, having to take action to arrange a test, having a test at the 
GP surgery/clinic and higher screening costs resulted in a decline 
in utility. The NN was associated with an increase in utility. Aside 
from the constant, the standard deviations for all coefficients were 
significant, suggesting considerable heterogeneity between women 
in their preferences. The standard deviation for the location coef‐
ficient was particularly large.
Table 4 reports the predictive analysis. Women appeared in‐
different between the current CSP and the use of PTAs; predicted 
probabilities of selecting each option were 0.503 and 0.497, respec‐
tively. Model predictions suggested both offered and sent SSKs 
were preferred to current screening practice. In contrast, current 
screening practice appeared preferable when compared with a pro‐
gramme in which a NN was offered as a standalone intervention.
3.3 | Comparing DCE and trial results
In the DCE predictive analysis, the sent HPV SSK was the most pre‐
ferred alternative, which was also identified in the STRATEGIC trial 
as one of the two interventions potentially effective. The other in‐
tervention was the PTA, yet women in the DCE appeared indiffer‐
ent between a PTA and the current CSP. The offered HPV SSK was 
preferred by women in the DCE but was not effective in the trial, and 
in both studies, the NN did not appear to be considered beneficial 
by women.
4  | DISCUSSION
This DCE is the first to assess preferences for alternative means of 
delivering cervical screening in a group of young women reluctant 
to engage with the current NHS CSP. Additionally, the STRATEGIC 
study design afforded a unique opportunity to consider women’s 
stated preferences alongside observed behaviours in the trial, and 
so provides additional information to help interpret the trial findings.
The study was conducted in accordance with good practice guid‐
ance for DCEs.28‐30 Qualitative interviews, the published literature 
and expert opinion were used to identify attributes. Additionally, a 
cost attribute was included to allow estimation of the marginal mon‐
etary benefit women placed upon each of the remaining attributes. 
For example, the monetary value of the benefit achieved when mov‐
ing from a GP clinic setting to a home testing setting. However, as we 
were interested in women’s preferences for screening programmes 
as defined by combinations of attributes, we questioned the mean‐
ingfulness of these individual values and ultimately chose not to 
report them. Careful consideration was given to the experimental 
design in a bid to increase participation, the questionnaire was pi‐
loted, and the results used to inform sample size calculations for 
the main survey. Choice data were analysed using a discrete choice 
model accounting for different sources of random heterogeneity.
Almost 94% of women surveyed either strongly agreed or agreed 
with the statement ‘screening for cervical cancer is important’. This 
is a notable finding, which has been observed elsewhere. In conduct‐
ing interviews with young non‐attending women for example, Waller 
et al found many were positively disposed towards cervical screen‐
ing despite making a decision not to attend.2
The mean coefficients from the model (Table 3) showed that 
when holding all else constant, having to take action to arrange a test 
would result in a decline in utility when compared to not having to 
take action. Similarly, having a test at a GP surgery or clinic would re‐
sult in lower utility than using a HPV SSK at home. When considered 
in isolation, a NN appeared to increase utility as indicated by the co‐
efficient’s positive sign. These findings appear intuitive given what is 
known about women’s barriers to screening. There was considerable 
TA B L E  2   Characteristics of DCE respondents
Characteristics N = 222
Country of residence – n (%)
England 127 (57)
Scotland 92 (41)
I’d rather not say 3 (1)
Age in years – mean (SD) 24.6 (2.5)
England 26.4 (0.9)
Scotland 22.1 (1.8)
Missing 6
Ethnicity – n (%)
White British/Irish 174 (79)
Any other White background 15 (7)
Pakistani 11 (5)
Other 9 (4)
Indian 4 (2)
African 4 (2)
Bangladeshi 1 (0)
I’d rather not say 1 (0)
Missing 3
Highest level of education – n (%)
University 108 (49)
Further education to age 18 years 47 (21)
Vocational qualification 44 (20)
School leaver at age 16 13 (6)
I’d rather not say 10 (5)
Main activity – n (%)
Employed 127 (57)
Student (full or part‐time) 57 (26)
Homemaker looking after the family 18 (8)
Unemployed and seeking work 7 (3)
I’d rather not say 5 (2)
Unpaid voluntary work 4 (2)
Long‐term sick or disabled 4 (2)
Abbreviation: SD, standard deviation.
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heterogeneity between women in terms of their preferences for the 
location of the test. This is perhaps not surprising as this attribute 
will capture dual (and opposing) concerns relating to embarrassment 
(whereby home testing is preferred) and expertise required to per‐
form the test (whereby GP clinic‐based testing is preferred).
The ability to consider the DCE findings alongside the STRATEGIC 
trial results is a novel aspect of this work. In the DCE predictive anal‐
ysis, women stated an obvious preference for an alternative exem‐
plifying the use of a sent HPV SSK. The trial similarly showed sent 
HPV SSKs to be the most effective and cost‐effective intervention; 
however, it also unexpectedly revealed that many women screened 
after receiving a sent HPV SSK did not use the kit, but attended for 
conventional cytology screening.
A possible explanation is that there exists a sub‐group of 
women for whom home testing is not preferable. The DCE showed 
location was most important to women and revealed significant 
heterogeneity in preferences for this attribute. For some women, 
home may not be a safe or a private environment. Furthermore, 
research into women’s perspectives of HPV self‐testing has iden‐
tified concerns including low confidence in the ability to self‐sam‐
ple, worries that samples may be lost or contaminated in the post, 
that HPV tests may be inferior to cytology tests, and fears about 
a lack of professional input and low confidence in the test result.19 
Here, it is possible that uncertainties around the HPV SSK per se 
exerted a greater influence on women’s screening decisions than 
the general process of how self‐sampling is delivered as covered 
by the DCE. Given concerns around HPV SSKs, but with an accep‐
tance of the importance of screening, many women appeared to 
have been ‘nudged’ into attending for conventional cytology after 
receiving a kit at home.14
The trial also identified PTAs as a potentially effective option 
for increasing screening uptake, whereas women in the DCE ap‐
peared indifferent between routine screening appointments they 
make themselves and PTAs (Table 4). It is possible that differences 
exist between women’s preferences for hypothetical scenarios (in 
the DCE, women may have been communicating their general dis‐
like of clinic‐based testing per se, regardless of how the appointment 
was arranged) and the decisions they face in reality; women may 
still dislike clinic‐based tests but are more likely to respond to a PTA 
because it removes the onus on them to arrange an appointment, 
TA B L E  3   Results from the final random correlated parameter 
mixed logit model
Means
Random correlated parameter mixed 
logit modela
Coefficient (SE) P value
Constant −0.431 (0.126) .001
Action required by you?
Yes −0.521 (0.238) .029
Location of test
GP surgery/clinic −1.123 (0.425) .008
Nurse available for dis‐
cussion or help prior to 
appointment?
Yes 1.862 (0.336) .000
Cost of your test to the 
NHS
−2.234 (0.140) .000
Standard deviations Coefficient (SE) P value
Constant 0.207 (0.158) .190
Action required by you?
Yes 2.279 (0.346) .000
Location of test
GP surgery/clinic 6.328 (0.761) .000
Nurse available for dis‐
cussion or help prior to 
appointment?
Yes 2.695 (0.388) .000
Cost of your test to the 
NHS
1.269 (0.116) .000
Goodness of fit Value
Log‐likelihood −958.19
AIC/n 0.739
Number of parameters 20
Number of observa‐
tions (n)
2647
Number of women 222
Abbreviations: AIC, Akaike’s information criteria; SE, standard error.
aAn expanded version of these results including the 20‐parameter 
model is available from the authors on request. 
TA B L E  4   Comparison of predictions for each alternative 
proposed screening intervention with current screening practice
Choice between
Probability  
(95% CI)
Current practicea .503 (.434 to .579)
Timed appointmentb .497 (.421 to .566)
Current practicea .320 (.264 to .377)
Offered HPV SSKc .680 (.623 to .736)
Current practicea .299 (.250 to .357)
Sent HPV SSKd .701 (.643 to .750)
Current practicea .571 (.513 to .635)
Nurse navigatore .429 (.365 to .487)
Abbreviation: HPV SSK, self‐sampling kit.
aAttribute levels for current practice are – action, yes; location, GP/
clinic; nurse, no; cost £25. 
bAttribute levels as for current practice with exception of action, which 
is switched from yes to no. 
cAttribute levels as for current practice with exception of location, 
which is switched from GP/clinic to home, and cost, which is changed 
from £25 to £8. 
dAttribute levels as for current practice with the exception of action, 
which is switched from yes to no, location which is switched from GP/
clinic to home, and cost which is changed from £25 to £8. 
eAttribute levels as for current practice with the exception of nurse, 
which is switched from no to yes, and cost which is changed from £25 
to £40. 
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and, as discussed above, they recognize that a decision not to attend 
could potentially have life‐changing consequences.
In the DCE, the offered HPV SSK was preferred to the current 
CSP, but was not effective in the trial. Again it is possible that whilst 
women in principle prefer the idea of home testing, in reality, with 
only an offer of a HPV SSK, the onus is still on them to request a kit. 
For many, this may still be a difficult first step to take.
Finally, the DCE suggested a screening programme incorporating 
a NN may be less preferable to women than the current CSP spec‐
ification. Analogously, the trial showed the offer of a NN to have a 
detrimental impact upon screening uptake. As the trial investigators 
hypothesized the apparent need for a NN may have further height‐
ened women’s anxieties and negative perceptions of screening.14,15
Similar findings, where hypothetical choices differ from real 
choices, have been observed elsewhere and are considered to be 
due to hypothetical bias.31 This bias is consequence driven; in real 
scenarios, real consequences follow a decision and participants make 
choices in the knowledge of this. In DCEs, where participants face 
no consequences as a result of the choices they make, this is thought 
to alter and bias their responses.31 Considering this in the context 
of STRATEGIC, and in the case of PTAs, this would fit well with our 
hypotheses that whilst women in the DCE were indifferent between 
making or receiving an appointment, women receiving a PTA in the 
trial might possibly have considered the potential consequences of 
ignoring that appointment too great a risk, despite their dislike of 
cytology screening. We must, however, be cautious in drawing such 
conclusions, as the DCE could not fully depict all interventions as de‐
livered in the trial. It was not possible to provide women in the DCE 
with detailed information about how to conduct and return a HPV 
SSK; rather, women were told only that they could undertake a simi‐
lar test at home. The availability of differing amounts of information 
to women is also likely to have influenced their choices.
This study is not without limitations. In developing the attributes 
and levels, only five women were interviewed; however, drawing on 
the literature and expert views ensured confidence in the final set 
used for the DCE. The response rate of just 5.5% to the DCE is also a 
concern. Despite efforts to increase participation, the defining char‐
acteristic of this cohort of women, that is that they are non‐engaged, 
meant that engaging them with a DCE about a screening programme 
in which they have chosen not to participate was challenging. Other 
DCEs in the area of cervical screening have similarly reported low 
response rates in sub‐groups of women eligible for but not attend‐
ing screening.32 As non‐responding women are likely to be the most 
at‐risk group, future studies may need to explore alternative ways 
of engaging such women to understand the issues they face with 
regard to cervical screening.
Given the low response rate, there is potential for non‐re‐
sponse error. However, it is difficult to know how we might have 
mitigated this further. Watson et al used meta‐regression to iden‐
tify factors of DCEs influencing response rates, and reported 
more than 2‐4 attributes were associated with reduced response 
rates but failed to find a negative association between response 
rates and the number of attribute levels.33 The use of reminders 
increased response rates, but the way this survey had to be ad‐
ministered (the details of women were known only to the screen‐
ing agencies) meant the research team were unable to monitor 
responses and send out reminders. The low response rate raises 
obvious questions about the generalizability of the study findings. 
Whilst our DCE results appear to be intuitive and commensurate 
with previous research on barriers to cervical screening, we must 
nevertheless exercise caution in drawing wider generalized con‐
clusions from our work.
Finally, it is important to consider the implications of recent 
changes to the cervical screening environment for the findings re‐
ported here. HPV vaccination of girls aged 12 to 13, for example, 
has been offered by the NHS since 2008, and in September 2019 
will be extended to boys of the same age.34 Studies have reported 
significant reductions in low‐ and high‐grade cervical intraepithelial 
neoplasia amongst those vaccinated, yet maintain that HPV vaccina‐
tion in combination with regular cervical screening is the best way 
to prevent against cervical cancer, as vaccination does not protect 
against all types of cancer‐causing HPV.35 Research into the effec‐
tiveness and acceptability of interventions, which increase the likeli‐
hood of a young women attending for cervical screening, therefore, 
continues to be paramount.
5  | CONCLUSIONS
This paper presents previously unreported data on the stated pref‐
erences of a group of hard to reach young women for the character‐
istics of interventions, which could potentially be embedded within 
the NHS CSP to increase screening uptake. In the DCE as well as 
the STRATEGIC trial, the sent SSK was the most preferred/effective 
alternative. Women in the DCE strongly acknowledged the impor‐
tance of screening yet differed significantly in their preferences for 
the location of the test. This could offer a potential means of under‐
standing why many women screened after receiving the sent HPV 
SSK in the trial attended for conventional cytology.
Policies bringing unsolicited screening interventions directly to 
women appear likely to be most effective. Additionally, such inter‐
ventions might also cause women to contemplate the potential im‐
plications of not responding to the intervention (a PTA or HPV SSK) 
in front of them; however, this would need to be explored more fully 
by future research. The low DCE response rate and the potential 
implications for the generalizability of the results must be acknowl‐
edged. Future research in this area should consider whether such 
questionnaires, which may be intimidating for respondents, offer the 
best means of engaging with a hard to reach cohort of women.
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